Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion criteria (FRANCE):~* Written informed consent (must be obtained prior initiation of any study related intervention)~* Female of age ≥18 years to ≤35 years~* Healthy as a result of review of medical history and/or clinical examination at the time of screening and clinical judgment of the investigator~* Available for the duration of the trial (15 months)~* Willingness to use reliable contraceptive methods such as: birth control pills or birth control patches or vaginal ring, diaphragm, IUD (intrauterine device), condom, progestin implant or injection, or surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation) prior to enrollment at V0 and up to 4 weeks after last vaccination (V6)~* Volunteer reachable by phone during the entire study duration~* Individuals affiliated to a social security regimen~* Volunteer registered in the French Health ministry computerized file and authorized to participate in a clinical trial~Exclusion criteria (FRANCE):~* Pregnancy ongoing as determined by a positive blood test or breastfeeding or lactation.~* Intention to become pregnant during the trial~* Volunteers who are not able to understand and to follow all required study procedures for the whole period of the study in the opinion of the investigator.~* Volunteers with history of any illness that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.~* Volunteers participating in any clinical trial with another investigational product 28 days prior to first study visit or intent to participate in another clinical study at any time during the conduct of this study.~* History of psychiatric condition that may affect participation in the study (i.e. depression, anti-depressant treatment).~* Prior receipt of an investigational malaria vaccine or any other investigational vaccine likely to impact on interpretation of the study data based on investigator's judgment.~* Any history of malaria infection.~* Travel to a malaria endemic region during the study period or within the six months preceding enrolment in the study.~* Volunteer has had medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* History of a serious adverse reaction to any vaccine, including Guillain-Barre Syndrome.~* Administration or planned administration of a vaccine or gammaglobulin not foreseen by the clinical trial protocol within 30 days prior to the first immunization and up to 4 weeks after the last immunization.~* Volunteers with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.~* Administration of immunoglobulins and/or any blood products within the three months preceding the inclusion.~* Any confirmed or suspected immunosuppressive or immunodeficient state; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 3 months (inhaled and topical steroids are allowed)~* Seropositive for hepatitis B virus surface antigen (HBsAg)~* Seropositive for hepatitis C virus (antibodies to HCV)~* Seropositive for human immunodeficiency virus (antibodies to HIV 1-2)~* Any other serious chronic illness requiring hospital specialist supervision.~* Any clinically significant abnormal finding on screening biochemistry or hematology blood tests or urinalysis~* Symptoms, physical signs or laboratory values suggestive of systemic disorders, including infectious renal, hepatic, cardiovascular, pulmonary, cutaneous, immunodeficiency, psychiatric and other conditions, which could interfere with the interpretation of the trial results or compromise the health of the volunteers.~* Volunteer under guardianship or legal incapacitation.~Inclusion criteria (BURKINA FASO):~* Written informed consent (must be obtained prior initiation of any study related intervention)~* Nulligest Female of age ≥18 years to ≤35 years~* Healthy as a result of review of medical history and/or clinical examination at the time of screening and clinical judgment of the investigator~* Available for the duration of the trial (15 months)~* Willingness to use reliable contraceptive methods such as: birth control pills or birth control patches or vaginal ring, diaphragm, IUD (intrauterine device), condom, progestin implant or injection, or surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation) prior to enrollment at V0 and up to 4 weeks after last vaccination (V6)~Exclusion criteria (BURKINA FASO):~* Pregnancy ongoing as determined by a positive urinary test~* Intention to become pregnant during the trial~* Volunteers who are not able to understand and to follow all required study procedures for the whole period of the study in the opinion of the investigator.~* Volunteers with history of any illness that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.~* Volunteers participating in any clinical trial with another investigational product 28 days prior to first study visit or intent to participate in another clinical study at any time during the conduct of this study.~* History of psychiatric condition that may affect participation in the study (i.e. depression, anti-depressant treatment).~* Prior receipt of an investigational malaria vaccine or any other investigational vaccine likely to impact on interpretation of the trial data, based on investigator's judgment.~* Volunteer has had medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* History of a serious adverse reaction to any vaccine, including Guillain-Barre syndrome.~* Administration or planned administration of a vaccine or gammaglobulin not foreseen by the clinical trial protocol within 30 days prior to the first immunization and up to 4 weeks after the last immunization.~* Volunteers with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.~* Administration of immunoglobulins and/or any blood products within the three months preceding the inclusion.~* Any confirmed or suspected immunosuppressive or immunodeficient state; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 3 months (inhaled and topical steroids are allowed).~* Seropositive for hepatitis B virus surface antigen (HBsAg).~* Seropositive for hepatitis C virus (antibodies to HCV).~* Seropositive for human immunodeficiency virus (antibodies to HIV 1-2).~* Any other serious chronic illness requiring hospital specialist supervision.~* Any clinically significant abnormal finding on screening biochemistry or hematology blood tests or urinalysis~* Symptoms, physical signs or laboratory values suggestive of systemic disorders, including renal, hepatic, cardiovascular, pulmonary, cutaneous, immunodeficiency, psychiatric and other conditions, which could interfere with the interpretation of the trial results or compromise the health of the volunteers.~* Volunteer under guardianship or legal incapacitation.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Group A1:Primvac 20 µg +alhydrogel (Type: EXPERIMENTAL): Group A1: 3 European volunteers 0.5 ml intramuscular injection: 20 µg Primvac+ 0.85 mg Alhydrogel®~Vaccination schedule: D0, D28 and D56
- Group A2:Primvac 20 µg +GLA-SE (Type: EXPERIMENTAL): Group A2: 3 European volunteers 0.5 ml intramuscular injection:20 µg Primvac+ 2.5 µg GLA-SE Vaccination schedule: D0, D28 and D56
- Group B1:Primvac 50 µg +alhydrogel (Type: EXPERIMENTAL): Group B1: 6 European volunteers 0.5 ml intramuscular injection: 50 µg Primvac+ 0.85 mg Alhydrogel®~Vaccination schedule: D0, D28 and D56
- Group B2:Primvac 50 µg +GLA-SE (Type: EXPERIMENTAL): Group B2: 6 European volunteers 0.5 ml intramuscular injection:50 µg Primvac+ 2.5 µg GLA-SE Vaccination schedule: D0, D28 and D56
- Group C1:Primvac 50 µg +alhydrogel (Type: EXPERIMENTAL): Group C1: 10 African volunteers 0.5 ml intramuscular injection: 50 µg Primvac+ 0.85 mg Alhydrogel®~Vaccination schedule: D0, D28 and D56
- Group C2: Primvac 50 µg +GLA-SE (Type: EXPERIMENTAL): Group C2: 10 African volunteers 0.5 ml intramuscular injection: 50 µg Primvac+ 2.5 µg GLA-SE~Vaccination schedule: D0, D28 and D56
- Group C3: Placebo (Type: PLACEBO_COMPARATOR): Group C3: 5 African volunteers 0.5 ml intramuscular injection: NaCl 0.9% (placebo)~Vaccination schedule: D0, D28 and D56
- Group D1:Primvac 100 µg +alhydrogel (Type: EXPERIMENTAL): Group D1: 10 African volunteers 0.6 ml intramuscular injection: 100µg Primvac+ 0.85 mg Alhydrogel®~Vaccination schedule: D0, D28 and D56
- Group D2: Primvac 100 µg +GLA-SE (Type: EXPERIMENTAL): Group D2: 10 African volunteers 0.6 ml intramuscular injection: 100 µg Primvac+ 2.56 µg GLA-SE~Vaccination schedule: D0, D28 and D56
- Group D3: placebo (Type: PLACEBO_COMPARATOR): Group D3: 5 African volunteers 0.6 ml intramuscular injection: NaCl 0.9% (placebo)~Vaccination schedule: D0, D28 and D56

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete